Clinical Laserthermia Systems (CLS) Q3 2025 earnings summary

Executive summary

• Achieved FDA clearance for expanded labeling of the ClearPoint Prism Neuro Laser Therapy System, doubling the addressable U.S. market for neurosurgery applications.

• Positive clinical safety study results for laser ablation in malignant brain tumor patients, showing increased median survival versus open surgery.

• Strategic focus on neurosurgery segment and partnership expansion outside neurosurgery to diversify revenue and reduce risk.

Financial highlights

• Q3 2025 revenue was SEK 2.8 million, down from SEK 5.4 million year-over-year, mainly due to timing of deliveries and lower urology sales.

• Operating profit improved by SEK 2.3 million in Q3 and by SEK 21.4 million for the first nine months compared to the same periods last year.

• Net loss for Q3 was SEK -8.1 million, improved from SEK -13.0 million in Q3 2024; nine-month net loss was SEK -29.7 million, better than SEK -39.0 million last year.

• Earnings per share for Q3 was SEK -0.3, compared to SEK -1.0 in Q3 2024.

• Equity ratio increased to 89% at the end of Q3 2025 from 85% a year earlier.

Outlook and guidance

• Priorities include accelerating U.S. adoption of the Prism system, advancing regulatory initiatives in Europe, expanding partnerships outside neurosurgery, and optimizing margins.

• Targeting positive cash flow by end of 2026 through focus on neurosurgery commercialization and cost efficiency.